ARTICLE | Product R&D
Modality moves at Vertex
How Vertex hopes to reach more patients with Arbor's CRISPR tools
January 18, 2019 3:40 AM UTC
In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address.
On Jan. 3, Vertex announced a deal with Arbor Biotechnologies Inc. that gives it access to novel CRISPR endonucleases -- the workhorse enzymes of the technology -- allowing the company to sidestep the complex IP landscape surrounding the more commonly used CRISPR-Cas9 (see “Plenty of CRISPR Pie.”)...
BCIQ Target Profiles